SCHEMBL6359191

SCHEMBL6359191

CCC(NCC(=O)c1ccccc1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
MAPT P10636 4/20 0.48
HPGD P15428 4/20 0.48
KDM4E B2RXH2 3/20 0.48
CYP3A4 P08684 2/20 0.48
MAPK1 P28482 2/20 0.48
ALOX15 P16050 1/20 0.48
CES1 P23141 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
TSHR P16473 1/20 0.46
DPP4 P27487 1/20 0.46
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 5/20 0.44
POLB P06746 1/20 0.44
AGTR1 P30556 2/20 0.43
PTPN1 P18031 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6359192 1.00 KMT2A (0.48) KMT2AMEN1SMN1; SMN2MAPTHPGD
SCHEMBL6348182 0.83 DPP4 (0.47) KMT2AMEN1SMN1; SMN2MAPTHPGD
SCHEMBL14900822 0.83 TSHR (0.47) KMT2AMEN1SMN1; SMN2MAPTHPGD
SCHEMBL5869355 0.83 DPP4 (0.47) KMT2AMEN1SMN1; SMN2MAPTHPGD
SCHEMBL2323847 0.83 MEN1 (0.48) KMT2AMEN1SMN1; SMN2MAPTHPGD
SCHEMBL7724205 0.83 KMT2A (0.48) KMT2AMEN1SMN1; SMN2MAPTHPGD
SCHEMBL6347909 0.82 KMT2A (0.47) KMT2AMEN1SMN1; SMN2MAPTHPGD
SCHEMBL6347905 0.82 KMT2A (0.47) KMT2AMEN1SMN1; SMN2MAPTHPGD
SCHEMBL7468481 0.81 SIGMAR1 (0.51) KMT2AMEN1SMN1; SMN2MAPTHPGD
SCHEMBL17944509 0.81 SIGMAR1 (0.51) KMT2AMEN1SMN1; SMN2MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 KMT2A 3612/4885MEN1 3756/4885SMN1; SMN2 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.